In vitro assessment of the effect of vaccine-targeted human papillomavirus (HPV) depletion on detection of non-vaccine HPV types: Implications for post-vaccine surveillance studies

Journal of Virological Methods

Volumn 214, Issue , 2015, Pages 10-14

  Cornall, Alyssa M ^a,b   Phillips, Samuel ^a,b   Cummins, Eleanor ^a,b   Garland, Suzanne M ^a,b,c   Tabrizi, Sepehr N ^a,b,c  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

False negatives; Genotyping; HPV; Surveillance; Type replacement; Vaccine

Indexed keywords

ARTICLE; DRUG SURVEILLANCE PROGRAM; GENOTYPE; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 59; IMMUNOSURVEILLANCE; IN VITRO STUDY; LIMIT OF DETECTION; POLYMERASE CHAIN REACTION; PREVALENCE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; VIRUS GENOME; VIRUS LOAD; WART VIRUS; CLASSIFICATION; COINFECTION; GENETICS; HUMAN; ISOLATION AND PURIFICATION; LABORATORY DIAGNOSIS; MOLECULAR DIAGNOSIS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; SENSITIVITY AND SPECIFICITY;

HUMAN PAPILLOMAVIRUS;

VIRUS DNA;

COINFECTION; DNA, VIRAL; FALSE NEGATIVE REACTIONS; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 84920181957     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2014.12.007     Document Type: Article

References (16)

1. Bernard H.U. The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J. Clin. Virol. 2005, 32(Suppl. 1):S1-S6.
2. Cornall A.M., Roberts J., Garland S.M., Hillman R., Grulich A.E., Tabrizi S. Anal and perianal cancers exclusively associated with low-risk HPV genotypes 6 and 11. Int. J. Cancer 2013, 133:2253-2258.
3. Garland S.M., Brotherton J.M.L., Condon J.R., McIntyre P.B., Stevens M.P., Smith D.W., Tabrizi S.N., WHINURS study group Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program. BMC Med. 2011, 9.
4. Gravitt P.E., Peyton C.L., Alessi T.Q., Wheeler C.M., Coutlée F., Hildesheim A., Schiffman M.H., Scott D.R., Apple R.J. Improved amplification of genital human papillomaviruses. J. Clin. Microbiol. 2000, 38:357-361.
5. Halpern A.L. Comparison of papillomavirus and immunodeficiency virus evolutionary patterns in the context of a papillomavirus vaccine. J. Clin. Virol. 2000, 19:43-56.
6. Jeronimo J., Wentzensen N., Long R., Schiffman M., Dunn S.T., Allen R.A., Walker J.L., Gold M.A., Zuna R.E., Sherman M.E., Wacholder S., Wang S.S. Evaluation of linear array human papillomavirus genotyping using automatic optical imaging software. J. Clin. Microbiol. 2008, 46:2759-2765.
7. Kahn J.A., Brown D.R., Ding L., Widdice L.E., Shew M.L., Glynn S., Bernstein D.I. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics 2012, 130:e249-e256.
8. Mejlhede N., Pedersen B.V., Frisch M., Fomsgaard A. Multiple human papilloma virus types in cervical infections: competition or synergy?. APMIS 2010, 118:346-352.
9. Merikukka M., Kaasila M., Namujju P.B., Palmroth J., Kirnbauer R., Paavonen J., Surcel H.-M., Lehtinen M. Differences in incidence and co-occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33. Int. J. Cancer 2011, 128:1114-1119.
10. Pagliusi S.R., Teresa Aguado M. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004, 23:569-578.
11. Pons-Salort M., Letort V., Favree M., Heard I., Dervaux B., Opatowski L., Guillemot D. Exploring individual HPV coinfections is essential to predict HPV-vaccination impact on genotype distribution: a model-based approach. Vaccine 2013, 31:1238-1245.
12. Stevens M.P., Rudland E., Garland S.M., Tabrizi S.N. Assessment of MagNA pure LC extraction system for detection of human papillomavirus (HPV) DNA in PreservCyt samples by the Roche AMPLICOR and linear array HPV tests. J. Clin. Microbiol. 2006, 44.
13. Tabrizi S.N., Brotherton J.M., Kaldor J.M., Skinner S.R., Liu B., Bateson D., McNamee K., Garefalakis M., Phillips S., Cummins E., Malloy M., Garland S.M. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect. Dis. 2014, 14:958-966.
14. Tabrizi S.N., Brotherton J.M.L., Kaldor J.M., Skinner R., Cummins E., Liu B., Bateson D., McNamee K., Garefalakis M., Garland S.M. Fall in human papillomavirus prevalence following a national vaccination program. J. Infect. Dis. 2012, 206:1645-1651.
15. Tota J.E., Ramanakumar A.V., Jiang M., Dillner J., Walter S.D., Kaufman J.S., Coutlée F., Villa L.L., Franco E.L. Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination. Am. J. Epidemiol. 2013, 178:625-634.
16. Tota J.E., Ramanakumar A.V., Villa L.L., Richardson H., Burchell A.N., Koushik A., Mayrand M.-H., Coutlée F., Franco E.L. Evaluation of human papillomavirus type replacement post-vaccination must account for diagnostic artifacts: masking of HPV52 by HPV16 in anogenital specimens. Cancer Epidemiol. Biomarkers Prev. 2014, (published online October 2). 10.1158/1055-9965.EPI-14-0566.